The most-sold recovery protocol in the category just had two of its three components clear an FDA advisory committee. That is a real event and it changes less than the marketing implies. Here is the stack, the evidence, and the part that got louder after July 23.
What the stack is
| Compound | Premise | PCAC July 2026 | Human evidence |
|---|---|---|---|
| BPC-157 | Gut and soft-tissue repair | 8–6–1 recommended | Extensive rodent work; injectable human trials essentially absent |
| TB-500 | Connective tissue, wound healing | 8–6–1 recommended | Thinner still |
| GHK-Cu | Matrix remodeling, skin | Not on the July docket | Most human data of the three; largely topical/cosmetic |
The post-vote framing problem
Within hours of the July 23 votes, the stack was being marketed as newly legitimized. Three corrections are worth stating plainly.
A favorable PCAC vote is not an efficacy finding. The question in front of the committee was compounding eligibility under 503A, not whether these compounds work. Dissenting members warned specifically that the public would read a yes as endorsement.
The FDA's own reviewers said no. Career staff applied the four-factor framework and recommended against all seven nominated peptides, citing thin human data and unresolved chemical characterization. The committee overrode them on six. The override is the news; it is not evidence.
GHK-Cu was not even on the docket. Any messaging implying the whole stack advanced is simply wrong. GHK-Cu is reportedly slated for a later session, expected around February 2027, and for non-injectable routes specifically.
A non-binding recommendation entered the record for two of the three compounds, starting a rulemaking clock estimated at 8–24 months. If it completes, the resulting access is a prescription pathway through a compounding pharmacy — clinician evaluation, documented medical need, cash pay. That is a meaningfully different product from a research vial, at a meaningfully different price.
The evidence, without the enthusiasm
BPC-157
The preclinical literature is genuinely large and genuinely interesting — tendon, ligament, muscle, and gut models across many rodent studies. The gap is the one FDA reviewers identified: there is essentially no controlled human trial data for injectable use. Anyone telling you the animal work translates is asserting, not reporting.
TB-500
Marketed as a Thymosin Beta-4 derivative, typically sold as a synthetic fragment rather than the intact parent peptide. The naming ambiguity is not pedantry — it means two vials with the same label can contain different molecules. Human data is thinner than BPC-157's.
GHK-Cu
The best-documented of the three in humans, and the documentation is mostly dermatological and topical. Extrapolating cosmetic topical findings to systemic connective-tissue repair is a large step that the literature does not take for you.
The stacking logic, examined
The case for combining is that the compounds hit different aspects of tissue repair and might be complementary. That is plausible. It is also unfalsifiable in practice for an individual user: if you run three compounds simultaneously alongside a modified training load and improved sleep, you have no way to attribute anything.
If you are going to run any of this, running one variable at a time is the only version that generates information rather than a story.
For tendinopathy and soft-tissue injury, progressive loading protocols have controlled human trial evidence that nothing on this page approaches. If the stack is being considered as a substitute for structured rehab rather than an addition to it, the expected value is negative regardless of what the compounds do.
Sourcing, since the channel has not changed
Research-grade material remains research-grade material. The July votes did not create pharmacy access and did not improve anyone's manufacturing. What determines the contents of the vial is unchanged: whether the supplier publishes lot-specific third-party analysis including identity confirmation, not just purity.
Suppliers stocking the stack components
Frequently Asked
Most commonly BPC-157 and TB-500, often with GHK-Cu added. The premise is combining a gut-and-tissue repair compound, a connective-tissue and wound-healing compound, and a copper peptide with skin and matrix-remodeling associations.
No. BPC-157 and TB-500 both received favorable advisory recommendations on July 23, 2026, each 8–6 with one abstention. Those are non-binding recommendations that begin a rulemaking process estimated at 8 to 24 months. Nothing about legal status changed. GHK-Cu was not on the July docket at all — it is reportedly slated for a later session.
Thin across all three. BPC-157 has extensive rodent work and essentially no controlled human injectable trial data, which was the FDA reviewers’ explicit finding. TB-500 has even less. GHK-Cu has the most human data of the three, and most of it is topical and cosmetic rather than systemic and orthopedic.
Yes. BPC-157 and TB-500 are both prohibited under anti-doping rules. FDA compounding policy has no bearing on WADA status — they are separate systems.
It increases uncertainty, which is the more honest framing. Each compound has an incomplete safety picture in humans; combining them means combining unknowns, and any adverse response becomes harder to attribute to a source.